Betsy Gray
Director Pfizer
Seminars
Thursday 19th March 2026
Preclinical Development of a Potent STING Agonist ADC
2:15 pm
- STING is an innate, antiviral immune pathway that can be co-opted to elicit antitumor immunity but must be tightly controlled to avoid toxic systemic immune activation.
- We describe a novel, tumor-targeted STING agonist ADC that drives robust antitumor activity in a variety of preclinical murine tumor models.
- We discuss how drug-linker design, target antigen, as well as Fcγ receptor binding impact ADC activity.
